

**Global Surveillance of Antiretroviral Drug Safety
Perspectives from Different Stakeholders**

Renaissance Hotel
Washington, DC
June 11, 2010

Judith A. Aberg, MD
NYU School of Medicine

Nyasha Bakare, MD, MPH
Forum for Collaborative HIV Research

Stephen Becker, MD
Bill & Melinda Gates Foundation

Barbara Da Silva-Tillmann, MD
Abbott

Gerald J. Dal Pan, MD, MHS
FDA

Rob Dintruff
Abbott

Alex Dodoo, PhD
University of Ghana Medical School

Chris Duncombe, MB, BS
World Health Organization

**Ivor Ralph Edwards, MB, CHB, MR CS, MAACT,
FRCP, FRACP**
WHO / Uppsala Monitoring Centre

Ngozi Erondy, MD, PhD
Global Alliance for TB Drug Development

Robert Ferris, DO, MPH
USAID

Benjamin Hauschild, MPH
Forum for Collaborative HIV Research

Ricardo Kuchenbecker, MD, MSc, PhD
Hospital de Clinicas de Porto Alegre, Brazil

Vijaya Kuppa, Pharm.D
Aurobindo Pharma Ltd.

Fabio Lievano, MD
Merck Sharp & Dohme Corp.

Marie Lindquist, PhD
The Uppsala Monitoring Centre (UMC)

Veronica Miller, PhD
Forum for Collaborative HIV Research

Albert Mwangi, BScHB, MBChB
Ministry of Health, Zambia

Joel Novendstern, MD
Ranbaxy

Jude Nwokike, MS, MPH
Management Sciences for Health (MSH)

June M. Raine, MD
Medicines and Healthcare Products Regulatory Agency

LuLu Oguda Mwangi, MD, MPH
EGPAF

James F. Rooney, MD
Gilead Sciences

Praphan Phanuphak, MD, PhD

Ian Sanne, MBBCH, FCP, DTM&H
Wits Health Consortium

David H. Brown Ripin, PhD
Clinton Health Access Initiative

Andy Stergachis, PhD
University of Washington

Caroline Ryan, MD
Office of the US Global AIDS Coordinator,
PEPFAR

Melissa Truffa, BS Pharm RPh
FDA / Office of Surveillance and Epidemiology

Carlie Williams, PhD
Division of AIDS

Jur Strobos, MD, JD, FACEP
Forum for Collaborative HIV Research

Marco Vitoria, MD
World Health Organization

Serge Xueref, PharmD, MSC, PhD
The Global Fund to fight AIDS, TB and Malaria